Shire plc (SHPG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
203.05-1.17 (-0.57%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close204.22
Bid167.86 x 100
Ask205.00 x 400
Day's Range202.59 - 204.31
52wk Range147.60 - 231.32
1y Target EstN/A
Market Cap60.48B
P/E Ratio (ttm)42.20
Avg Vol (3m)1,199,965
Dividend & Yield0.80 (0.40%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Amgen, Biogen Pitted In M&A Scenario; Adamas, Acadia Draw Interest
    Investor's Business Daily2 days ago

    Amgen, Biogen Pitted In M&A Scenario; Adamas, Acadia Draw Interest

    Amgen and Biogen could square off to acquire muscle biologist Cytokinetics, while many players look at Adamas Pharmaceuticals.

  • Reuters2 days ago

    Shire raises eyebrows with stunning debut

    Investors piled into the debut bond from Shire this week, ignoring some clear warning signals that the drugmaker's deal might have offered a little bit less than meets the eye. The US$12.1bn trade amassed a US$28.5bn order book, even as analysts were noting that Shire's debt-to-Ebitda ratio had jumped from less than one time to more than seven times in 12 months. Proceeds will help finance Shire's US$32bn hostile takeover of rival Baxalta, and some of the buyside demand could be put down to investor appetite for all things pharma.

  • PR Newswire3 days ago

    Shire to Showcase Continued Innovation and Leadership in Immune Deficiencies During European Society for Immunodeficiencies Biennial Meeting

    Shire plc (LSE: SHP, NASDAQ: SHPG) will showcase data across its global leading immunoglobulin (IG) portfolio during the 17th Biennial Meeting of the European Society for Immunodeficiencies (ESID), taking place September 21-24, 2016 in Barcelona. Presentations will include results of studies examining the safety, efficacy and tolerability profiles of Shire's IG treatment options for immune deficiencies, including primary immunodeficiency (PI). Shire will complement the data on treatment options with research on the burden PI patients experience relating to their disease and treatment, as part of Shire's commitment to delivering advanced, individualized treatment options for people with PI.